Title: President Trump Announces New Round of Drug Price Deals with Nine Pharmaceutical Companies
In an effort to address the rising costs of prescription drugs in the United States, President Trump has announced deals with nine pharmaceutical companies aimed at bringing drug prices more in line with those paid by other wealthy countries. This marks a significant step towards tackling one of America's most pressing healthcare issues and could potentially save billions of dollars for both government programs like Medicaid and individual consumers who pay out-of-pocket for their medications.
The companies involved include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. These firms have agreed to charge the U.S government no more for new drugs than what other well-off countries pay, allowing state Medicaid programs access to lower prices from these nine companies.
In addition to reducing drug costs for Americans, the pharmaceutical giants also pledged to invest at least $150 billion in manufacturing operations within the United States as part of President Trump's push towards increasing domestic production of pharmaceuticals. This investment could lead to job creation and boost local economies across various states where these facilities will be established.
Furthermore, consumers who pay out-of-pocket for their medications can expect lower prices through a government website called TrumpRx.com which is set to launch in early 2026. This platform will direct users to pharmaceutical companies' direct-to-consumer websites where they can purchase drugs at discounted rates. For example, Merck has agreed to reduce the price of Januvia, a medication for Type 2 diabetes, from $330 to $100 when purchased through TrumpRx. Similarly, Amgen will lower the cost of Repatha, a cholesterol-lowering drug, from $573 to $239 when bought via this platform.
In exchange for these concessions, the pharmaceutical companies involved in the deals will be exempted from potential administration tariffs for three years. This move demonstrates President Trump's commitment towards addressing one of America's most pressing healthcare issues while also promoting domestic manufacturing and job creation within the country.
Overall, these new round of drug price deals represent a significant step forward in tackling rising prescription drug costs in the United States. With potential savings amounting to billions of dollars for both government programs like Medicaid and individual consumers who pay out-of-pocket for their medications, this initiative has the potential to significantly improve accessibility and affordability of essential medicines across America.
Source: [Original Article](https://www.npr.org/sections/shots-health-news/2025/12/19/nx-s1-5649920/trump-drug-prices) #white
Check out my AI projects on <a href='https://huggingface.co/ghostail'>Hugging Face</a>, join our community on <a href='https://discord.com/invite/zgKZUJ6V8z'>Discord</a>, and explore my services at <a href='https://ghostai.pro'>GhostAI</a>!